$7.00
1.75% yesterday
Nasdaq, Sep 04, 10:00 pm CET
ISIN
US7027121000
Symbol
PASG

Passage Bio Inc Stock price

$7.00
+1.26 21.95% 1M
-1.51 17.72% 6M
-4.34 38.28% YTD
-6.77 49.15% 1Y
-32.60 82.32% 3Y
-291.40 97.65% 5Y
-437.00 98.42% 10Y
-437.00 98.42% 20Y
Nasdaq, Closing price Thu, Sep 04 2025
-0.13 1.75%
ISIN
US7027121000
Symbol
PASG
Industry

Key metrics

Basic
Market capitalization
$21.8m
Enterprise Value
$-35.8m
Net debt
positive
Cash
$57.6m
Shares outstanding
3.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.0
P/B
0.6
Financial Health
Equity Ratio
59.8%
Return on Equity
-105.7%
ROCE
-104.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-59.9m | $-74.9m
EBIT
$-61.8m | $-46.3m
Net Income
$-56.9m | $-44.4m
Free Cash Flow
$-36.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
18.3% | -20.6%
EBIT
19.5% | 29.0%
Net Income
25.7% | 31.4%
Free Cash Flow
49.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-17.9
FCF per Share
$-11.3
Short interest
4.1%
Employees
60
Rev per Employee
$0.0
Show more

Is Passage Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Passage Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Passage Bio Inc forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a Passage Bio Inc forecast:

Buy
91%
Hold
9%

Financial data from Passage Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 23 23
18% 18%
-
- Research and Development Expense 32 32
35% 35%
-
-60 -60
18% 18%
-
- Depreciation and Amortization 1.85 1.85
45% 45%
-
EBIT (Operating Income) EBIT -62 -62
19% 19%
-
Net Profit -57 -57
26% 26%
-

In millions USD.

Don't miss a Thing! We will send you all news about Passage Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Passage Bio Inc Stock News

Neutral
GlobeNewsWire
8 days ago
PHILADELPHIA, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held from September 8-10, 2025 in New York City.
Neutral
GlobeNewsWire
24 days ago
Completed dosing of FTD-GRN Cohort 2 in upliFT-D study Reported updated interim data showing that PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural history Submitted amended upliFT-D study protocol to global trial sites and health authorities Cash runway into 1Q 2027 PHILADELPHIA, Aug....
Neutral
GlobeNewsWire
about 2 months ago
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-20...
More Passage Bio Inc News

Company Profile

Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program; and The Trustees of the University of Pennsylvania for research and development collaborations, and exclusive license rights to patents for certain products and technologies. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.

Head office United States
CEO William Chou
Employees 60
Founded 2017
Website www.passagebio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today